ホーム › 膵臓がん › ノースカロライナ › Durham
Durham、NCにおける膵臓がんの臨床試験
Durhamとその周辺地域（約30マイル以内）の拠点で、膵臓がんに関する24件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
The Vanguard Study: Testing a New Way to Screen for Cancer
被験者募集中健康なボランティア歓迎
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10マイル先
A Study of PHN-012 in Patients With Advanced Solid Tumors
被験者募集中第1相
- PHN-012-001 Site, Durham
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
被験者募集中第3相
- Duke Cancer Center, Durham
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
被験者募集中第2/3相
- UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill · 10マイル先
- University of North Carolina Hospitals at Hillsborough, Hillsborough · 13マイル先
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
被験者募集中第3相
- Duke Cancer Center, Durham
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
被験者募集中第3相
- Investigative Site US035, Chapel Hill · 10マイル先
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
被験者募集中第1/2相
- Duke University Medical Center, Durham
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
被験者募集中第2相
- Local Institution - 0100, Durham
Promoting CT Engagement for Pancreatic Cancer With App
被験者募集中
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10マイル先
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
被験者募集中観察研究
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10マイル先
- University of North Carolina-Hillsborough Campus, Hillsborough · 13マイル先
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
被験者募集中第2相
- University of North Carolina, Chapel Hill · 10マイル先
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
被験者募集中第1相
- University of North Carolina - Gastroenterology and Hepatology, Chapel Hill · 10マイル先
- University of North Carolina, Chapel Hill · 10マイル先
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
被験者募集中第3相
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10マイル先
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
被験者募集中第1相
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10マイル先
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
被験者募集中第2相
- Duke University Medical Center, Durham
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
被験者募集中第1相
- Duke Cancer Institute /ID# 276267, Durham
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
被験者募集中第1相
- Research Site, Durham
Autologous CAR-T Cells Targeting B7-H3 in PDAC
被験者募集中第1相
- University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill · 10マイル先
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
被験者募集中第1相
- Duke Cancer Center, Durham
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
被験者募集中第1/2相
- University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill · 10マイル先
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
被験者募集中第2相
- University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill · 10マイル先
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Chapel Hill · 10マイル先
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
被験者募集中第2相
- University of North Carolina, Chapel Hill · 10マイル先
他の都市における膵臓がんの試験
- Houston, TX61件の研究
- New York City, NY60件の研究
- Boston, MA43件の研究
- Nashville, TN39件の研究
- Los Angeles, CA35件の研究
- St. Louis, MO33件の研究
- Arlington, VA33件の研究
- Baltimore, MD31件の研究
- San Antonio, TX31件の研究
- Philadelphia, PA26件の研究
- Tampa, FL26件の研究
- San Diego, CA24件の研究
Durhamにおける他の研究
- 乳がん64件の研究
- がん（全種類）58件の研究
- 非小細胞肺癌39件の研究
- 多発性骨髄腫37件の研究
- 急性骨髄性白血病33件の研究
- 転移性癌33件の研究
- 前立腺がん32件の研究
- 肺がん32件の研究
- 大腸癌28件の研究
- 卵巣がん27件の研究
- 慢性リンパ性白血病27件の研究
- 心不全26件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。